Literature DB >> 23908113

Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Adam J Gehring1, Muzlifah Haniffa, Patrick T Kennedy, Zi Zong Ho, Carolina Boni, Amanda Shin, Nasirah Banu, Adeline Chia, Seng Gee Lim, Carlo Ferrari, Florent Ginhoux, Antonio Bertoletti.   

Abstract

Selection of antigens for therapeutic vaccination against chronic viral infections is complicated by pathogen genetic variations. We tested whether antigens present during persistent viral infections could provide a personalized antigenic reservoir for therapeutic T cell expansion in humans. We focused our study on the HBV surface antigen (HBsAg), which is present in microgram quantities in the serum of chronic HBV patients. We demonstrated by quantitative fluorescent microscopy that, out of 6 professional APC populations in the circulation, only CD14 monocytes (MNs) retained an HBsAg depot. Using TCR-redirected CD8+ T cells specific for MHC-I-restricted HBV epitopes, we showed that, despite being constantly exposed to antigen, ex vivo-isolated APCs did not constitutively activate HBV-specific CD8+ T cells. However, differentiation of HBsAg+ CD14 MNs from chronic patients to MN-derived DCs (moDCs) induced cross-presentation of the intracellular reservoir of viral antigen. We exploited this mechanism to cross-present circulating viral antigen and showed that moDCs from chronically infected patients stimulated expansion of autologous HBV-specific T cells. Thus, these data demonstrate that circulating viral antigen produced during chronic infection can serve as a personalized antigenic reservoir to activate virus-specific T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908113      PMCID: PMC3754243          DOI: 10.1172/JCI66043

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance.

Authors:  A Limmer; J Ohl; C Kurts; H G Ljunggren; Y Reiss; M Groettrup; F Momburg; B Arnold; P A Knolle
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

3.  CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.

Authors:  Robert Thimme; Stefan Wieland; Carola Steiger; John Ghrayeb; Keith A Reimann; Robert H Purcell; Francis V Chisari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.

Authors:  W Lu; J M Andrieu
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells.

Authors:  Detlef Stober; Zlatko Trobonjaca; Jörg Reimann; Reinhold Schirmbeck
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

6.  Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells.

Authors:  Z Fan; X L Huang; L Borowski; J W Mellors; C R Rinaldo
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection.

Authors:  Susanne Beckebaum; Vito R Cicinnati; Grzegorz Dworacki; Jan Müller-Berghaus; Donna Stolz; Jo Harnaha; Theresa L Whiteside; Angus W Thomson; Lina Lu; John J Fung; C Andrew Bonham
Journal:  Clin Immunol       Date:  2002-08       Impact factor: 3.969

8.  Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

Authors:  Una Lazdina; Mats Alheim; Jessica Nyström; Catharina Hultgren; Gallina Borisova; Irina Sominskaya; Paul Pumpens; Darrell L Peterson; David R Milich; Matti Sällberg
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

9.  Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

Authors:  Dao-Zhen Xu; Xuan-Yi Wang; Xin-Liang Shen; Guo-Zhong Gong; Hong Ren; Li-Min Guo; Ai-Min Sun; Min Xu; Lan-Juan Li; Xin-Hui Guo; Zhen Zhen; Hui-Fen Wang; Huan-Yu Gong; Cheng Xu; Nan Jiang; Chen Pan; Zuo-Jiong Gong; Ji-Ming Zhang; Jia Shang; Jie Xu; Qing Xie; Tie-Feng Wu; Wen-Xiang Huang; Yong-Guo Li; Jing Xu; Zheng-Hong Yuan; Bin Wang; Kai Zhao; Yu-Mei Wen
Journal:  J Hepatol       Date:  2013-05-11       Impact factor: 25.083

10.  Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells.

Authors:  M Mohamadzadeh; F Berard; G Essert; C Chalouni; B Pulendran; J Davoust; G Bridges; A K Palucka; J Banchereau
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  36 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 3.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

4.  Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection.

Authors:  Jiezuan Yang; Jiajia Chen; Jianqin He; Yirui Xie; Yixing Zhu; Hongcui Cao; Lanjuan Li
Journal:  Cell Mol Immunol       Date:  2014-07       Impact factor: 11.530

5.  Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.

Authors:  Ludovic Aillot; Marc Bonnin; Malika Ait-Goughoulte; Nathalie Bendriss-Vermare; Sarah Maadadi; Laura Dimier; Miroslava Subic; Caroline Scholtes; Isabel Najera; Fabien Zoulim; Julie Lucifora; David Durantel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 6.  Immune Response in Hepatitis B Virus Infection.

Authors:  Anthony Tan; Sarene Koh; Antonio Bertoletti
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

Review 7.  Host-virus interactions in hepatitis B and hepatitis C infection.

Authors:  Sachiyo Yoshio; Tatsuya Kanto
Journal:  J Gastroenterol       Date:  2016-02-19       Impact factor: 7.527

8.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

Authors:  Jang-June Park; David K Wong; Abdus S Wahed; William M Lee; Jordan J Feld; Norah Terrault; Mandana Khalili; Richard K Sterling; Kris V Kowdley; Natalie Bzowej; Daryl T Lau; W Ray Kim; Coleman Smith; Robert L Carithers; Keith W Torrey; James W Keith; Danielle L Levine; Daniel Traum; Suzanne Ho; Mary E Valiga; Geoffrey S Johnson; Edward Doo; Anna S F Lok; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2015-12-10       Impact factor: 22.682

Review 9.  Hepatitis B virus large surface protein: function and fame.

Authors:  Yuri Churin; Martin Roderfeld; Elke Roeb
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

Review 10.  Advances in therapeutics for chronic hepatitis B.

Authors:  Ninghan Yang; Antonio Bertoletti
Journal:  Hepatol Int       Date:  2015-09-12       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.